IL-13R alpha 1 Antibody (MK-6105) [DyLight 405]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28311V
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 405 (Excitation = 400 nm, Emission = 420 nm)
Antibody Source
Recombinant Monoclonal Human IgG2 Clone # MK-6105
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
IL-13Ra1 / CD213a1
Clonality
Monoclonal
Host
Human
Isotype
IgG2
Applications for IL-13R alpha 1 Antibody (MK-6105) [DyLight 405]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-13 R alpha 1
Long Name
Interleukin 13 Receptor alpha 1
Alternate Names
CD213a1, IL-13Ra1, IL13R alpha 1, IL13RA1
Gene Symbol
IL13RA1
Additional IL-13 R alpha 1 Products
Product Documents for IL-13R alpha 1 Antibody (MK-6105) [DyLight 405]
Product Specific Notices for IL-13R alpha 1 Antibody (MK-6105) [DyLight 405]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...